2009 Fiscal Year Final Research Report
Drug discovery research based on the molecular mechanisms of tumor growth and metastasis
| Project/Area Number |
17016079
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research on Priority Areas
|
| Allocation Type | Single-year Grants |
|---|
| Review Section |
Biological Sciences
|
|---|
| Research Institution | The Institute of Physical and Chemical Research |
|---|
Principal Investigator |
OSADA Hiroyuki The Institute of Physical and Chemical Research, ケミカルバイオロジー研究基盤施設, 施設長 (80160836)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KANOH Naoki 独立行政法人理化学研究所, 長田抗生物質研究室, 先任研究員 (40317293)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
SUDO Tatsuhiko 独立行政法人理化学研究所, 化合物ライブラリー評価研究チーム, 先任研究員 (30260227)
MUROI Makoto 独立行政法人理化学研究所, 化合物ライブラリー評価研究チーム, 先任研究員 (30261168)
UEKI Masashi 独立行政法人理化学研究所, 化学情報・化合物創製チーム, 先任研究員 (90312264)
SIMIZU Siro 独立行政法人理化学研究所, 化合物ライブラリー評価研究チーム, 専任研究員 (30312268)
|
|---|
| Project Period (FY) |
2005 – 2009
|
| Keywords | ケミカルバイオロジー / 癌転移 / 血管新生 / 天然化合物 / プロテオーム |
|---|
| Research Abstract |
The purpose of this study is to clarify the molecular mechanisms of tumor growth and metastasis, and to develop new anticancer agents using microbial metabolites and chemical library. We exhibited some new molecular targets through the analysis of metastasis-related proteins such as RECK and heparanase, and developed proteomic profiling system for classification of compounds according to the mechanism of action. In addition, we developed various anticancer lead compounds including reveromycin A (bone metastasis inhibitor9), epoxyquinol B (antiangiogenic agent), methyl-gerfelin (osteoclastogenesis inhibitor), and purpurogallin (inhibitor of PBD dependent binding).
|
